Cannabis use disorder tracked with persistently higher suicidal thoughts across a decade
A large U.S. analysis has drawn a sharp line between casual marijuana use and cannabis use disorder. Among more than 415,000 adults surveyed from 2014 through 2023, people with the disorder had 57% higher odds of reporting suicidal thoughts than people without it. The association held across the full study period, despite sweeping changes in marijuana policy, social acceptance, and product availability.
The result is clinically important because it separates a common substance from a distinct psychiatric syndrome marked by loss of control, continued use despite harm, and repeated difficulty cutting back. In that setting, the question is no longer simply whether someone uses cannabis. The sharper question is whether cannabis-related impairment is coexisting with a level of psychological vulnerability that can place suicidal thinking within reach.
Women and younger adults carried the heaviest burden in the dataset. The elevated odds were also seen across different age groups, sexes, and racial and ethnic backgrounds, which argues against a narrow or isolated pattern. The signal persisted after adjustment for depression, psychological distress, and other factors tied to mental health outcomes, leaving an association that remained substantial even after common confounders were considered.
What the numbers mean in everyday practice
A 57% increase in odds does not mean cannabis use disorder is the sole driver of suicidal ideation, and it does not mean every patient with the disorder is at imminent risk. It does mean the disorder should trigger more deliberate psychiatric screening than a routine substance-use history alone might suggest.
That is the practical consequence at the bedside. A patient asking for help with cannabis dependence may be struggling with silent suicidal thoughts that never surface unless a clinician asks directly. In primary care, emergency settings, addiction treatment, and behavioral health clinics, that question can change the trajectory of care in a single visit.
The study’s design supports association, not causation. It cannot determine whether problematic cannabis use contributes to suicidal thinking, whether preexisting psychiatric distress increases vulnerability to both, or whether another unmeasured factor helps explain the connection. Even so, the persistence of the signal over 10 years argues against a short-lived anomaly or a shift created solely by changing laws and social norms.
Why the finding matters as cannabis potency and access have changed
The timing makes the findings harder to ignore. Recreational marijuana is now legal in half of U.S. states, and cannabis products have become more potent over time. Those changes have reshaped public perception, lowered perceived risk, and widened access. In parallel, people with cannabis use disorder remain a group in which serious mental health symptoms can hide behind a substance that many now view as relatively benign.
There is a biological and behavioral logic to the concern. Cannabis use disorder often reflects repeated exposure, impaired self-regulation, and continued use despite harm, features that can cluster with anxiety, depression, and psychosocial stress. When a patient is already psychologically strained, a substance-use disorder may serve less as an isolated habit and more as one layer of a broader clinical burden. The data do not prove mechanism, but they support careful mental status assessment rather than assumptions based on the drug alone.
What stood out most in the decade-long analysis was stability. The association did not appear to intensify from 2014 to 2023, despite the rapid expansion of legalization and changing social attitudes. Suicidal ideation did not surge in lockstep with those public changes among people with cannabis use disorder, yet the elevated odds never disappeared.
Screening needs to move beyond the substance itself
The clearest clinical implication is mental health screening. Patients with cannabis use disorder may benefit from direct questions about suicidal thoughts, recent hopelessness, self-harm behavior, and the severity of depressive symptoms. Waiting for a patient to volunteer that information misses the reality that suicidal ideation is often concealed, minimized, or not recognized as reportable by the person experiencing it.
This is especially relevant for younger adults and women, the subgroups with particularly elevated risk in the analysis. Those groups already account for a large share of patients seen in outpatient behavioral health and substance-use settings, and the finding suggests the threshold for asking about suicide should be low. The point is not to presume suicidality. The point is to identify who needs closer evaluation, immediate support, or a more intensive treatment plan.
Clinicians should also resist a simplistic reading of the data. The study does not imply that all marijuana use is equally dangerous or that occasional use carries the same risk profile as disorder-level use. The distinction between use and use disorder is central. One reflects exposure; the other reflects impaired control and functional harm, which is the clinical state linked to the elevated odds of suicidal thoughts.
A public health signal that should not be blurred by normalization
Public acceptance of cannabis has changed rapidly, but normalization can obscure severity when use crosses into disorder. The study makes clear that problem cannabis use remains a mental health concern even in a period of broader legalization and greater social tolerance. For health systems, that means screening protocols, referral pathways, and crisis assessment procedures need to keep pace with changing patient behavior and changing assumptions.
For policymakers and community programs, the finding supports broader awareness campaigns that separate casual use from cannabis use disorder while making it easier for vulnerable individuals to reach mental health care. For clinicians, the actionable step is much narrower: ask about suicidal thoughts when cannabis use disorder is present, and do not wait for an obvious signal.
The study’s own limitations keep the interpretation grounded. It cannot establish direction of causality, and it does not explain the full mechanism behind the association. Even so, the consistency of the signal across a large national sample, a decade of data, and multiple demographic strata makes the message difficult to dismiss: cannabis use disorder belongs on the list of conditions that should prompt explicit suicide risk assessment, not because it proves suicidal intent, but because it reliably coexists with it often enough to matter.
- • Journal Study DOI 10.15288/jsad.25-00481: https://doi.org/10.15288/jsad.25-00481